Cardiac organoid®-Nuoxinte Biotechnology (Suzhou) Co., Ltd

Cardiac organoid®

Product Description | hiPSC-Derived cardiac organoids

NUOXINTE Biotechnology is committed to providing high-quality cardiac organoid® derived from human induced stem cells (hiPSC) using optimized unique differentiation techniques。 cardiac organoid® is composed of over 95% of myocardial cells and has electrophysiological activity. Compared with 2D cardiomyocytes, the function of calcium regulation and contractility is improved, and the expression level of ion channels is higher. cardiac organoid® is suitable for all types of experiments in the field of myocardial cells, including tissue-specific studies, toxicity testing, and drug discovery.

Item No.	Products	Specifications
CO-002	Cardiac organoid® hiPSC-Derived cardiac organoids	About 500 organoids/tubes

Item No.

Products

Specifications

CO-002

Cardiac organoid®

hiPSC-Derived cardiac organoids

About 500 organoids/tubes

Product Introduction | hiPSC-Derived cardiac organoids

Morphology
Features
Electrophysiology

Morphology

On the 30th day of differentiation of Cardiac organoid®.

Cardiac organoid® is similar to 2D cardiomyocytes in that it can spontaneously beat.

Features

cTnT
VE-Cad
DAPI
Vim
a-Act
DAPI

Cardiac organoid® expresses cardiac myocyte specific genes (cTnT, a-Act) and endothelial cells (VE Cad); Fibroblasts (Vim).

Cardiac organoid® is composed of over 92% of myocardial cells and has higher functions in calcium regulation and contractility than 2D myocardial cells.

Electrophysiology

Cardiac organoid® was tested for electrophysiological function and drug responsiveness evaluation on a 48 well MEA plate. White/red represents peak activity; Blue/black represents low peak activity.